SciClone Pharmaceuticals, Inc. : SciClone Announces Board of Directors and Officer Changes



SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the resignation of Trevor M. Jones, Ph.D., C.B.E., from the Board of Directors. Prof. Jones made this decision based on the increasing demands of his other professional obligations, including his involvement in a new business venture and his service on several other boards of directors. Prof. Jones has been a member of the SciClone Board since 2009. 

Jon Saxe, SciClone's Chairman, commented: "The SciClone Board of Directors would like to express our sincere gratitude to Trevor for his service and for the contributions he has made to the Company's significant progress. We appreciate his years of strong support and counsel, his scientific insight, his elegance, his good humor and the dedication and leadership with which he fulfilled his commitment to SciClone. We wish him very well in his current and future endeavors." 

Separately, the Company announced that Dr. Israel Rios has resigned as of April 6, 2012. Dr. Rios departure was related to the Company's winding down of its U.S.-based product development programs. 

Friedhelm Blobel, SciClone's Chief Executive Officer, said: "Israel has been an outstanding member of our executive team for over six years, consistently contributing to our business in a positive way. I would like to thank Israel for his service and we all wish him well in his future efforts." 

The membership of the Board of Directors of the Company will be reduced from eight members to seven members following Dr. Jones departure

No comments:

Post a Comment

Superhit News

News Archive